We are pleased to announce that the 1st Collaborative Assessment of WP4 AC-B on “Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk” is ready now available.
The EC-EUnetHTA Forum "European cooperation on HTA: what's next?" co-organised by the European Commission and the EUnetHTA Joint Action 3 was the first meeting between all 79 EUnetHTA partner organisations and the broader HTA stakeholder community.
The Forum entitled “European Cooperation on HTA: What’s next?” is jointly organized by the European Commission and EUnetHTA and EC on the 21st of October 2016 in Brussels (The Square conference center).
On the 7th June 2016, a technical meeting was held in Paris, hosted by Haute Autorité de Santé (HAS, EUnetHTA Work Package 5 lead). The participants of this meeting not only included all EUnetHTA Joint Action 3 WP leads, but also representatives from industry (pharmaceutical), European Federation of Pharmaceutical Industries and Associations (EFPIA), European Medicines Agency (EMA), HTA agencies and the European Commission.
The Dutch National Health Care Institute and the European Commission signed the Grant Agreement on the 25th of August 2016. Within 30 days all organisations need to sign in order to join the creation of sustainable HTA network. Then Joint Action 3 will start officially.